Key result
Very early invasive angiography trial in N-STEMI ends prematurely due to COVID-19 and low events.
Why the study?
Randomised data on the optimal timing of invasive coronary angiography in higher-risk N-STEMI patients are limited, with guidelines relying primarily on retrospective subgroup analyses.
Does very early invasive coronary angiography improve clinical outcomes compared to standard of care timing in higher-risk N-STEMI patients?
RCT (n=425)
Open-label
Yes
Does very early invasive coronary angiography improve clinical outcomes compared to standard of care timing in higher-risk N-STEMI patients?
The RAPID N-STEMI trial protocol outlines a randomized comparison of very early versus standard timing of invasive angiography in high-risk N-STEMI patients, though the trial was discontinued early due to the COVID-19 pandemic.
Answers are grounded in this paper and cite their sources.
Stopped early by pandemic, very early angiography timing remains unproven in higher-risk N-STEMI; leaves optimal strategy open for future trials.
BACKGROUND: There are a paucity of randomised data on the optimal timing of invasive coronary angiography (ICA) in higher-risk patients with non-ST elevation myocardial infarction (N-STEMI). International guideline recommendations for early ICA are primarily based on retrospective subgroup analyses of neutral trials. AIMS: The RAPID N-STEMI trial aims to determine whether very early percutaneous revascularisation improves clinical outcomes as compared with a standard of care strategy in higher-risk N-STEMI patients. METHODS AND ANALYSIS: RAPID N-STEMI is a prospective, multicentre, open-label, randomised-controlled, pragmatic strategy trial. Higher-risk N-STEMI patients, as defined by Global Registry of Acute Coronary Events 2.0 score ≥118, or >90 with at least one additional high-risk feature, were randomised to either: very early ICA±revascularisation or standard of care timing of ICA±revascularisation. The primary outcome is the proportion of participants with at least one of the following events (all-cause mortality, non-fatal myocardial infarction and hospital admission for heart failure) at 12 months. Key secondary outcomes include major bleeding and stroke. A hypothesis generating cardiac magnetic resonance (CMR) substudy will provide mechanistic data on infarct size, myocardial salvage and residual ischaemia post percutaneous coronary intervention. On 7 April 2021, the sponsor discontinued enrolment due to the impact of the COVID-19 pandemic and lower than expected event rates. 425 patients were enrolled, and 61 patients underwent CMR. ETHICS AND DISSEMINATION: The trial has been reviewed and approved by the East of England Cambridge East Research Ethics Committee (18/EE/0222). The study results will be submitted for publication within 6 months of completion. TRIAL REGISTRATION NUMBER: NCT03707314; Pre-results.
No takes yet. Share an insight, caveat, or question.
Kite et al. (2022) conducted an RCT in Higher-risk non-ST elevation myocardial infarction (N-STEMI) (n=425). Very early invasive coronary angiography (ICA) ± revascularisation vs. Standard of care timing of ICA ± revascularisation was evaluated on Composite of all-cause mortality, non-fatal myocardial infarction and hospital admission for heart failure at 12 months. Very early invasive angiography versus standard of care in higher-risk N-STEMI enrolled 425 patients before premature discontinuation due to the COVID-19 pandemic and lower than expected event rates.
Synapse has enriched 10 related papers. Consider them for comparative context: